PartnerTech signs framework agreement with Dignitana AB (publ)

Contract manufacturer PartnerTech AB and Dignitana AB (publ), a company focusing on medical devices in the area of medical cooling, today announced the signing of a framework agreement for the development, manufacturing and supply of products to Dignitana AB.

Initially, the agreement will focus on the DigniCapTMSystem, a patented scalp cooling system which prevents chemotherapy induced hair loss. The agreement covers the full scale of PartnerTech's competences within electronics, mechanics, systems integration and enclosures, and production will initially cover enclosures delivered from PartnerTech's unit in Åtvidaberg, Sweden. Revenue and the first deliveries from this agreement are expected in the third quarter 2012.

Dignitana has during the last year signed on two major international healthcare partners, Konica Minolta MG and Sysmex Europe GmbH, a subsidiary of Sysmex Corporation, and will substantially increase the level of production to meet the demand from the market and their partners.

" We have been working very close with Dignitana and one of their partners in the implementation of improvements and preparation for start-up of production of the DigniCapTMSystem. Dignitana is an innovative company, both in terms of technology and business development, and we are very pleased that they have chosen PartnerTech as a key partner for the long term development and production of their products," says PartnerTech President and CEO Leif Thorwaldsson.

"The next phase of Dignitana starts now, having established a solid industrial platform. Since more than a year back we have been working with the team at PartnerTech in different projects and, in close cooperation with and influenced by our two key Japanese partners, we have established a long term partnership with PartnerTech both for production and development", says Martin Waleij, CEO Dignitana.

For more information, please contact:

Leif Thorwaldsson, President and CEO, PartnerTech AB , Tel: +46 (0) 40 10 26 41

Martin Waleij, CEO Dignitana AB, Tel: +46 - 733 93 70 76

PartnerTech

PartnerTech develops and manufactures products under contract for leading companies, primarily in Information Technology, Industry, CleanTech, MedTech and Instrumentation, Defense and Maritime and Point of Sale Applications. With approximately 1,300 employees at its plants in Sweden, Norway, Finland, Poland, the UK, the United States and China PartnerTech reports annual sales of more than SEK 2,3 billion. PartnerTech AB (www.partnertech.com), the parent company, has its head office in Vellinge, Sweden, and is listed on the Nasdaq OMX Stockholm Exchange.

PartnerTech AB, corporate identity number 556251-3308

Box 103, Industrigatan 2, SE-235 22 Vellinge, Sweden

PartnerTech (publ) is required to publicly disclose the information in this press release pursuant to the Swedish Securities Market Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for public disclosure at 11 a.m. on August 20th, 2012.

Dignitana

Dignitana AB, listed on the OMX First North Stockholm, focuses on patented invention DigniCap™ system , a medical device for preventing hair-loss in chemotherapy patients throug


Dignitana tillförs 42 miljoner SEK i en riktad nyemission av units

Dignitana AB (publ) ("Dignitana" eller "Bolaget") meddelade idag att Bolaget har genomfört en framgångsrik riktad nyemission av units bestående av aktier och teckningsoptioner, vilket tillför Dignitana cirka 42 miljoner SEK före emissionskostnader. Likviden från nyemissionen kommer användas för att kraftfullt öka tillväxttakten i Bolaget med fokus på den nya skalpkylningsmaskinen, DigniCap Delta, som både är CE- och FDA-godkänd. Delta systemet medför även en förbättrad global intjäningsmodell bestående av engångs- och flergångsintäkter. Vid fullt utnyttjande av samtliga teckningsoptioner tillförs Bolaget ytterligare 42 miljoner SEK före emissionskostnader.


Dignitana receives SEK 42 million in a directed new issue of units

Dignitana AB (publ) ("Dignitana" or the "Company") today announced that the Company has successfully conducted a directed new issue of units consisting of shares and warrants, which has now raised proceeds to Dignitana of SEK 42 million before deduction of issue costs. These proceeds will be used to aggressively increase the growth rate of the company with a focus on the new scalp cooling device, DigniCap Delta. This new FDA cleared and CE marked system introduces an improved global business model consisting of one-time and recurring revenue. At full exercise of the warrants, Dignitana will be provided with additional SEK 42 million before deduction of issue costs.


Dignitana avser att genomföra en riktad nyemission av units

Dignitana AB (publ) ("Dignitana" eller "Bolaget") meddelade idag att Bolaget avser att, med stöd av bemyndigande från årsstämma den 15 maj 2019, genomföra en nyemission av units bestående av aktier och teckningsoptioner med avvikelse från aktieägarnas företrädesrätt som riktas till kvalificerade investerare i Sverige och internationella institutionella investerare (den "Riktade emissionen").


Dignitana intends to make a directed new issue of units

Dignitana AB (publ) ("Dignitana" or the "Company") today announces its intention to execute a directed share issue of units consisting of shares and warrants with deviation from the shareholders' preferential rights, directed to qualified investors in Sweden and international institutional investors, as authorized by the annual general meeting on 15 May 2019 (the" Directed New Issue").


Delårsrapport Q2 2019

Financial highlights

  •  Total revenue for the Group amounted to 12,002 TSEK, 1,275 KUSD which is an increase of 33 percent over the same period 2018.
  •  Year to date revenue for the Group was 22,109 TSEK, 2,350 KUSD, an increase of 47 percent over the same period 2018.

Business highlights  

  •  FDA clearance of the next generation DigniCap Delta June 2019.  
  •  First European installation of DigniCap Delta at Gemelli University Hospital in Rome, Italy, in May 2019.  
  •  Contracts were signed for 19 locations in the United States, bringing the total number of signed U.S. sites to 139 across 30 states at the close of second quarter.  
  •  The Company continued efforts to initiate legislation providing insurance coverage for scalp cooling with a Bill (HB 3984) introduced in Texas and discussions are underway with legislators in three other states.  
  •  Dignitana co-sponsored a scalp cooling session at the Multinational Association for Supportive Care in Cancer Annual meeting in San Francisco, California in June 2019.  

Dignitana AB Publishes Q2 2019 Interim Report

Financial highlights

  •  Total revenue for the Group amounted to 12,002 TSEK, 1,275 KUSD which is an increase of 33 percent over the same period 2018.
  •  Year to date revenue for the Group was 22,109 TSEK, 2,350 KUSD, an increase of 47 percent over the same period 2018.

Business highlights  

  •  FDA clearance of the next generation DigniCap Delta June 2019.  
  •  First European installation of DigniCap Delta at Gemelli University Hospital in Rome, Italy, in May 2019.  
  •  Contracts were signed for 19 locations in the United States, bringing the total number of signed U.S. sites to 139 across 30 states at the close of second quarter.  
  •  The Company continued efforts to initiate legislation providing insurance coverage for scalp cooling with a Bill (HB 3984) introduced in Texas and discussions are underway with legislators in three other states.  
  •  Dignitana co-sponsored a scalp cooling session at the Multinational Association for Supportive Care in Cancer Annual meeting in San Francisco, California in June 2019.  

Dignitana delivers first DigniCap Delta in United States

Next generation scalp cooling device minimizes hair loss from chemotherapy


Dignitana AB Publishes August Newsletter

Dignitana AB today publishes the August 2019 edition of the company newsletter, attached to this release.



Dignitana får FDA-godkännande i USA för DigniCap Delta scalp cooling system

Nästa generations kliniskt överlägsna skalpkylningssystem minskar håravfallet hos cancerpatienter


Dignitana receives FDA clearance for DigniCap Delta scalp cooling system

Clinically superior next generation device reduces hair loss for cancer patients


Dignitana AB Publishes June Newsletter

Dignitana AB today publishes the June 2019 edition of the company newsletter, attached to this release.


Dignitana installs the first DigniCap Delta Scalp Cooling System in Rome

Dignitana ABmanufacturer of The DigniCap® Scalp Cooling System, has announced installation of the first DigniCap Delta at the prestigious Gemelli University Hospital in Rome, Italy last month.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär